263 related articles for article (PubMed ID: 16133112)
1. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials.
Sakamoto J; Morita S; Oba K; Matsui T; Kobayashi M; Nakazato H; Ohashi Y;
Cancer Immunol Immunother; 2006 Apr; 55(4):404-11. PubMed ID: 16133112
[TBL] [Abstract][Full Text] [Related]
2. Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa).
Mitomi T; Tsuchiya S; Iijima N; Aso K; Suzuki K; Nishiyama K; Amano T; Takahashi T; Murayama N; Oka H
Dis Colon Rectum; 1992 Feb; 35(2):123-30. PubMed ID: 1735313
[TBL] [Abstract][Full Text] [Related]
3. [Randomized controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum].
Mitomi T; Tsuchiya S; Iijima N; Aso K; Suzuki K; Nishiyama K; Amano T; Takahashi T; Murayama N; Oka H
Gan To Kagaku Ryoho; 1989 Jun; 16(6):2241-9. PubMed ID: 2500070
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of adjuvant immunochemotherapy with OK-432 for patients with curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials.
Sakamoto J; Teramukai S; Nakazato H; Sato Y; Uchino J; Taguchi T; Ryoma Y; Ohashi Y
J Immunother; 2002; 25(5):405-12. PubMed ID: 12218778
[TBL] [Abstract][Full Text] [Related]
5. Immunochemotherapy with PSK and fluoropyrimidines improves long-term prognosis for curatively resected colorectal cancer.
Sakai T; Yamashita Y; Maekawa T; Mikami K; Hoshino S; Shirakusa T
Cancer Biother Radiopharm; 2008 Aug; 23(4):461-7. PubMed ID: 18771350
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of immunochemotherapy with PSK, a protein-bound polysaccharide, in colorectal cancer and changes of tumor marker.
Kudo S; Tanaka J; Kashida H; Tamegai Y; Endo S; Yamano HO
Oncol Rep; 2002; 9(3):635-8. PubMed ID: 11956642
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study.
Ohwada S; Ikeya T; Yokomori T; Kusaba T; Roppongi T; Takahashi T; Nakamura S; Kakinuma S; Iwazaki S; Ishikawa H; Kawate S; Nakajima T; Morishita Y
Br J Cancer; 2004 Mar; 90(5):1003-10. PubMed ID: 14997197
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer.
Oba K; Teramukai S; Kobayashi M; Matsui T; Kodera Y; Sakamoto J
Cancer Immunol Immunother; 2007 Jun; 56(6):905-11. PubMed ID: 17106715
[TBL] [Abstract][Full Text] [Related]
9. [Clinical results of a randomized controlled trial on the effect of adjuvant immunochemotherapy using Esquinon and Krestin in patients with curatively resected gastric cancer--7-year survival--Cooperative Study Group for Cancer Immunochemotherapy, Tokai Gastrointestinal Oncology Group].
Ichihashi H; Kondo T; Nakazato H
Gan To Kagaku Ryoho; 1987 Sep; 14(9):2758-66. PubMed ID: 3307635
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant therapy with protein-bound polysaccharide K and tegafur uracil in patients with stage II or III colorectal cancer: randomized, controlled trial.
Ohwada S; Kawate S; Ikeya T; Yokomori T; Kusaba T; Roppongi T; Takahashi T; Nakamura S; Kawashima Y; Nakajima T; Morishita Y;
Dis Colon Rectum; 2003 Aug; 46(8):1060-8. PubMed ID: 12907900
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of adjuvant immunochemotherapy in advanced gastric cancer].
Sakamoto J; Nakazato H
Gan To Kagaku Ryoho; 1993 Dec; 20(16):2525-30. PubMed ID: 8279851
[TBL] [Abstract][Full Text] [Related]
12. Preoperative CEA and PPD values as prognostic factors for immunochemotherapy using PSK and 5-FU.
Takahashi Y; Mai M; Nakazato H
Anticancer Res; 2005; 25(2B):1377-84. PubMed ID: 15865094
[TBL] [Abstract][Full Text] [Related]
13. Impact of splenectomy and immunochemotherapy on survival following gastrectomy for carcinoma: covariate interaction with immunosuppressive acidic protein, a serum marker for the host immune system. Tumor Marker Committee for the Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Saji S; Sakamoto J; Teramukai S; Kunieda K; Sugiyama Y; Ohashi Y; Nakazato H
Surg Today; 1999; 29(6):504-10. PubMed ID: 10385364
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of adjuvant immunochemotherapy with OK-432 after curative resection of gastric cancer: an individual patient data meta-analysis of randomized controlled trials.
Oba MS; Teramukai S; Ohashi Y; Ogawa K; Maehara Y; Sakamoto J
Gastric Cancer; 2016 Apr; 19(2):616-624. PubMed ID: 25804300
[TBL] [Abstract][Full Text] [Related]
15. Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) of Japan.
Morimoto T; Ogawa M; Orita K; Sugimachi K; Toge T; Dohi K; Nomura Y; Monden Y; Ogawa N
Eur J Cancer; 1996 Feb; 32A(2):235-42. PubMed ID: 8664034
[TBL] [Abstract][Full Text] [Related]
16. Immunochemotherapy benefits in gastric cancer patients stratified by programmed death-1 ligand-1.
Hsu JT; Hsu CS; Le PH; Chen TC; Chou WC; Lin CY; Yeh TS
J Surg Res; 2017 May; 211():30-38. PubMed ID: 28501128
[TBL] [Abstract][Full Text] [Related]
17. Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy.
Fisher M; Yang LX
Anticancer Res; 2002; 22(3):1737-54. PubMed ID: 12168863
[TBL] [Abstract][Full Text] [Related]
18. Beneficial effects of protein-bound polysaccharide K plus tegafur/uracil in patients with stage II or III colorectal cancer: analysis of immunological parameters.
Ohwada S; Ogawa T; Makita F; Tanahashi Y; Ohya T; Tomizawa N; Satoh Y; Kobayashi I; Izumi M; Takeyoshi I; Hamada K; Minaguchi S; Togo Y; Toshihiko T; Koyama T; Kamio M
Oncol Rep; 2006 Apr; 15(4):861-8. PubMed ID: 16525672
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of adjuvant immunochemotherapy using OK-432 in patients with resected non-small-cell lung cancer.
Sakamoto J; Teramukai S; Watanabe Y; Hayata Y; Okayasu T; Nakazato H; Ohashi Y;
J Immunother; 2001; 24(3):250-6. PubMed ID: 11394503
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulation in colorectal cancer: disappointment or promise?
Pentheroudakis G; Pavlidis N
Ann Oncol; 2003 Mar; 14(3):349-51. PubMed ID: 12598336
[No Abstract] [Full Text] [Related]
[Next] [New Search]
